Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays

Nelson, Scott M.; Pastuszek, Ewa; Kloss, G; Malinowska, Iwona; Liss, Joanna; Łukaszuk, Aron; Płóciennik, Łukasz; Łukaszuk, Krzysztof

doi:10.1016/j.fertnstert.2015.06.024

Cited by 98 publications

(89 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AMH was measured in the serum of all our cases by the referring physician. The results are not comparable because they were obtained with different methods [Nelson et al, 2015].…”

Section: Endocrine Investigationsmentioning

confidence: 84%

The Persistent Müllerian Duct Syndrome: An Update Based Upon a Personal Experience of 157 Cases

Picard¹,

Cate

Racine³

et al. 2017

Sex Dev

144

169

View full text Add to dashboard Cite

Male sex differentiation is driven by 2 hormones, testosterone and anti-müllerian hormone (AMH), responsible for the regression of müllerian ducts in male fetuses. Mutations inactivating AMH or its receptor AMHRII lead to the persistent müllerian duct syndrome (PMDS) in otherwise normally virilized 46,XY males. Our objective was to review the clinical, anatomical, and molecular features of PMDS based upon a review of the literature and upon 157 personal cases. Three clinical presentations exist: bilateral cryptorchidism, unilateral cryptorchidism with contralateral hernia, and transverse testicular ectopia. Abnormalities of male excretory ducts are frequent. Testicular malignant degeneration occurs in 33% of adults with the disorder, while cancer of müllerian derivatives is less frequent. Fertility is rare but possible if at least one testis is scrotal and its excretory ducts are intact. Eighty families with 64 different mutations of the AMH gene have been identified, mostly in exons 1, 2, and 5. AMHRII gene mutations representing 58 different alleles have been discovered in 75 families. The most common mutation, a 27-bp deletion in the kinase domain, was found in 30 patients of mostly Northern European origin. In 12% of cases, no mutation of AMH or AMHRII has been detected, suggesting a disruption of other pathways involved in müllerian regression.

show abstract

“…AMH was measured in the serum of all our cases by the referring physician. The results are not comparable because they were obtained with different methods [Nelson et al, 2015].…”

Section: Endocrine Investigationsmentioning

confidence: 84%

The Persistent Müllerian Duct Syndrome: An Update Based Upon a Personal Experience of 157 Cases

Picard¹,

Cate

Racine³

et al. 2017

Sex Dev

144

169

View full text Add to dashboard Cite

show abstract

“…It included a predilution step of the specimen in assay buffer before addition to the ELISA plate, which gave more reliable AMH results [55]. Currently, fully automatic measurements of serum AMH concentrations are also available (Elecsys, AMH, Roche and Access, AMH, Beckman Coulter) [56]. Moreover, new commercial AMH enzyme-linked immunosorbent assay (picoAMH ELISA, AnshLabs) with a lower threshold of detection is useful especially in women with diminished ovarian reserve [57].…”

Section: Amh In Pcos Diagnosismentioning

confidence: 99%

“…W 2013 roku wprowadzono modyfikację do oznaczeń II generacji, która polegała na dodatkowym rozcieńczeniu próbki, co dawało bardziej wiarygodne oznaczenia stężenia AMH w badanym materiale [55]. Obecnie, dostępne są w pełni zautomatyzowane metody do oznaczenia stężeń AMH w materiale biologicznym (Elecsys AMH, Roche oraz Acess, AMH, Beckam Coulter) [56]. Warto podkreślić, że dostępne są również nowe, bardziej czułe zestawy wykorzystujące metodę ELISA (picoAMH ELISA, AnshLabs), które pozwalają na oznaczanie niższych stężeń AMH.…”

Section: Amh W Diagnostyce Pcosunclassified

Hormon anty-müllerowski i zespół policystycznych jajników

Łebkowska

Kowalska

2015

Endokrynologia Polska

View full text Add to dashboard Cite

Anti-Müllerian hormone (AMH) is a glycoprotein, a member of the transforming growth factor β family, reflecting the number of ovarian antral follicles. Polycystic ovary syndrome (PCOS) is a common endocrinopathy predisposing to infertility, and metabolic and cardiovascular complications. In our review, we discuss the role of AMH in PCOS pathophysiology and its clinical applications according to the published studies. Improvement of AMH assay validity will allow the clinical utility of this valuable biomarker to be widened.

show abstract

“…The values derived from the Immunotech Beckman Coulter (IBC) assay and the Gen II Beckman Coulter assay were considered equivalent, as the Gen II assay was calibrated on the IBC assay standards . Similarly, the values from the Ansh lab assay were reported to be similar to the Gen II assay . Where pooling of data was not appropriate, a narrative summary including results from individual studies was presented.…”

Section: Methodsmentioning

confidence: 99%

Biomarkers of ovarian reserve in childhood and adolescence: A systematic review

Bhide

Pundir

Homburg

et al. 2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction Certain medical disorders as well as their management may affect gonadal function. Recent advances in the management of these conditions accompanied by the availability and success of methods of fertility preservation has highlighted the need for assessment of ovarian reserve in childhood and adolescence. Serum anti‐Mullerian hormone (AMH) and antral follicle count are well established markers of ovarian reserve and serum inhibin has also been used. However, literature on reference ranges for ovarian reserve markers in this age‐group is relatively scarce. Thus, our aim was to evaluate published data to estimate reference values of ovarian reserve makers in childhood and adolescence. Material and methods We performed a systematic review of the literature reporting ovarian reserve markers in childhood and adolescence. We included only those studies examining markers of ovarian reserve in the normal healthy population between the ages of 0 and 19 years. PROSPERO registration: CRD42018119064. Results Serum AMH emerged as the most common biomarker assessed. Serum AMH was detectable at birth and, after a transient increase in infancy, increased steadily in childhood. Following a slight decrease at puberty, levels were constant throughout adolescence with a peak in adolescence or early adulthood. The mean serum AMH values during infancy, childhood and adolescence were 10.55, 22.32 and 31.84 pmol/L, respectively. The corresponding median values were 9.85, 24.49 and 26.32 pmol/L. It was not possible to construct age‐specific reference intervals because of methodological heterogeneity, variations in the assay used to measure AMH and differing interval width for age used in included studies. Serum inhibin showed an increase from childhood to adolescence, with median serum inhibin values of 53.86 pg/mL in adolescence. Antral follicle count showed a significant positive correlation with serum AMH and a median value of 30.52 in adolescence. Conclusions We summarize the trends and levels of biomarkers of ovarian reserve from birth until young adulthood. Peak levels of serum AMH are reported in adolescence or early adulthood. We have reported median/mean values for serum AMH in different age‐groups based on data pooled from several studies, which may be used as a reference when evaluating ovarian reserve in childhood and adolescence especially when considering fertility preservation.

show abstract

Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays

Cited by 98 publications

References 22 publications

The Persistent Müllerian Duct Syndrome: An Update Based Upon a Personal Experience of 157 Cases

The Persistent Müllerian Duct Syndrome: An Update Based Upon a Personal Experience of 157 Cases

Hormon anty-müllerowski i zespół policystycznych jajników

Biomarkers of ovarian reserve in childhood and adolescence: A systematic review

Contact Info

Product

Resources

About